Investigation of Serious Adverse Events Following Vaccination Against Yellow Fever: Emphasis on Genetic Basis and Biological Markers

Drug-Related Side Effects and Adverse Reactions Clinical Trial

Official title:

Investigation of Serious Adverse Events Following Vaccination Against Yellow Fever: Emphasis on Genetic Basis and Biological Markers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03938597
• Other study ID #: ASCLIN002/2016
• Status: Recruiting
• Start date: January 30, 2017
• Est. completion date: December 2023

Study information

• Verified date: June 2023
• Source: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
• Contact: Patricia MN de Oliveira, MD, PhD
• Phone: 552138827000
• Email: patricia.mouta[@]bio.fiocruz.br
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

It concerns an investigation aiming to investigate genetic biological(s) marker(s) which allow to identify individuals who have risk of serious adverse events to the yellow fever vaccine. This testing is free of hypothesis, because these markers are still unknown. There is no intervention, and it is not possible to establish primary and secondary outcomes.

Description:

The rational for the immunological study by LATIM is the observation made by the group that individuals vaccinated with the 17DD yellow fever vaccine show significant alterations on the levels of expression of genes such as CLEC5A, IFNG, IL6, RNASEL, IRF7, IRF9, STAT2 e OAS1 (8). The study which will be conducted by the Rockefeller University will be focused in the qualitative analysis of the genome and exome of volunteers. The study in LATIM will be focused in the quantitative analysis of mRNA, which, together with the results of sequencing, may help in the search for biomarkers. As the expression of mRNA is restricted to the acute phase of the adverse event, it will be done only during the first 30 days after the beginning of the adverse event.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: December 2023
• Est. primary completion date: June 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 9 Months to 59 Years

Eligibility

Inclusion criteria:

• Evidence of a systemic reaction in two or more organs within one month of vaccination with yellow fever vaccine;
• Laboratory evidence of yellow fever vaccine virus (at least one):

Positive culture for more than 7 days after vaccination; RT-PCR = 3 log10 PFU/mL at any day after vaccination; Positive RT-PCR more than 14 days after vaccination; Presence of vaccine virus in tissue by culture, RT-PCR or immunohistochemistry.

• Laboratory exclusion of relevant differential diagnosis such as leptospirosis, viral hepatitis and arboviruses.
• Cases not obeying these strict criteria but that could be plausibly YEL-AVD or YEL-AND may be included, if approved by the investigator or co-investigators.

Exclusion Criteria:

• Cases with adverse event after yellow fever vaccine not severe.

Related Conditions & MeSH terms

• Drug-Related Side Effects and Adverse Reactions
• Yellow Fever

Locations

Country	Name	City	State
Brazil	Assessoria Clinica / Bio-Manguinhos / Fiocruz	Rio De Janeiro	RJ

Sponsors (2)

Lead Sponsor	Collaborator
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)	Rockefeller University

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Genetic markers	Whole exome sequencing (WES) will be performed in YEL-AVD cases.	Time frame: 5 years